# IMpassion030 (NCT03498716)

> A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03498716
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Triple Negative Breast Cancer
- Interventions: Atezolizumab; Paclitaxel; Dose-dense Doxorubicin or dose-dense Epirubicin; Cyclophosphamide
- Enrollment: 2199
- Primary outcome: Invasive Disease-Free Survival (iDFS)

## Commentary we found

- X threads: 24
- Podcasts: 9
- YouTube: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=impassion030-nct03498716

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03498716", "email": "<work email>"}; the inbox owner confirms by the emailed link.